Receptors, Agonists,
and Half-Life
A peptide does not do anything by itself. It is a message. This module covers what receives the message, what happens next, and how long the message lasts, which turns out to be the number that determines nearly every practical decision downstream.
The lock, and what the lock is attached to
A receptor is a protein that changes shape when a specific molecule binds to it. Because peptides generally cannot cross the cell membrane, peptide receptors sit on the cell surface with a binding site facing outward and a business end facing inward. Binding on the outside deforms the protein, and the deformation on the inside starts something.
Most peptide hormones act through G protein-coupled receptors, or GPCRs, the largest receptor family in the human genome and the target of a very large fraction of all drugs. The mechanism, in the amount of detail you need:
- The peptide binds the receptor's extracellular face.
- The receptor changes conformation.
- An associated G protein on the inner face is activated.
- That triggers a second messenger, often cyclic AMP, inside the cell.
- The second messenger activates enzymes, which change what the cell is doing: secreting something, transcribing a gene, contracting, growing.
The important structural feature of this arrangement is amplification. One bound peptide molecule can produce thousands of second-messenger molecules. This is why peptides are dosed in micrograms while, say, paracetamol is dosed in hundreds of milligrams. You are not supplying a reagent. You are pressing a switch.
Because the system amplifies, "more" does not scale the way intuition suggests. Once the available receptors are occupied, additional compound has nowhere to bind and produces no additional effect, but it can still produce additional off-target binding elsewhere. This is the mechanism behind the observation that raising a dose past a certain point buys side effects rather than results.
Agonist, antagonist, and the words in between
These terms appear on every vendor page and are used correctly on perhaps half of them.
| Term | Meaning |
|---|---|
| Agonist | Binds and activates the receptor, producing the same effect as the native signal. |
| Partial agonist | Binds and activates, but produces a submaximal effect even at full occupancy. |
| Antagonist | Binds without activating. Occupies the site and blocks the native signal. |
| Inverse agonist | Binds and suppresses activity below the receptor's baseline resting level. |
| Allosteric modulator | Binds elsewhere on the receptor and changes how it responds to its normal ligand. |
Two further properties are worth separating in your head, because conflating them causes real errors:
- Affinity. How tightly a compound binds. High affinity means it takes very little compound to occupy the receptor.
- Efficacy. How much effect the binding produces once it has happened.
A compound can have exceptional affinity and negligible efficacy: it sits in the receptor doing nothing and preventing anything else from doing anything either. That is an antagonist, and it is precisely how some drugs work on purpose. "Binds strongly" is therefore not a claim about potency; it is a claim about one of two independent variables.
Biased agonism
A refinement worth knowing because it explains why two compounds hitting the same receptor can behave differently. A single receptor often has more than one downstream pathway: the classical G-protein route and a separate β-arrestin route, for instance. Some ligands activate both; some preferentially activate one. That preference is called biased agonism, and it is one reason two GLP-1 receptor agonists can differ in side-effect profile despite nominally identical targets. If someone tells you two compounds are "the same thing, one is just cheaper", this is one of the several ways that can be false.
Dose-response
Plot effect against dose and you do not get a straight line. You get an S-curve: little happens at low doses, then a steep region where small increases produce large changes, then a plateau where the receptors are saturated and further dose does nothing useful.
The dose producing half the maximum effect is the EC50. It is the standard measure of potency, and it is a comparative number. It tells you how much of compound A you need relative to compound B, not how good either one is. A compound with a lower EC50 is more potent, which means only that less of it is required. It says nothing whatsoever about whether the effect is desirable.
Potency is not strength, efficacy is not benefit, and affinity is not either of them.
Half-life
The half-life (t½) is the time taken for the circulating concentration to fall by half. It is determined by how fast the compound is cleared (degraded by enzymes, filtered by the kidneys, taken up and metabolised by the liver), and it is the single most useful pharmacokinetic number for a peptide, because it governs three things at once.
1. Dosing frequency
A compound cleared in minutes cannot be dosed weekly, no matter how convenient that would be. The engineered half-life extensions covered in Module 01 exist entirely to move compounds from the first category to the second. The spread across the field is enormous:
| Compound | Approximate half-life | Implied schedule |
|---|---|---|
| Native GLP-1 | ~2 minutes | Continuous infusion only |
| Native GHRH | ~5-10 minutes | Not practical as a drug |
| Ipamorelin | ~2 hours | Multiple times daily |
| Liraglutide | ~13 hours | Daily |
| Tirzepatide | ~5 days | Weekly |
| Semaglutide | ~7 days | Weekly |
Figures are approximate and vary by route, formulation, and individual. They are given to show the range, not as reference values.
2. Time to steady state
Dose repeatedly at an interval shorter than full clearance and the compound accumulates: each dose lands on top of what remains of the last. Concentration climbs until the amount cleared per interval equals the amount administered per interval. That equilibrium is steady state, and as a rule of thumb it takes roughly four to five half-lives to reach.
Tirzepatide has a half-life of roughly five days. Four to five half-lives puts steady state at about 20 to 25 days, which is why a weekly-dosed compound takes the better part of a month to reach the level it is going to hold. That figure is not a separate fact to memorise. It falls out of the half-life and the rule above, and you can derive it for any compound the moment you know the number.
For a compound with a one-week half-life, that is four to five weeks. This has an immediate practical consequence that is widely misunderstood: the effect you feel in week one is not the effect of the dose you are taking. You are still climbing. Judging a compound's effects, or its side effects, before steady state is judging an incomplete process, and adjusting the dose during that window means you are chasing a number that was going to move anyway.
3. Washout
Clearance runs on the same clock. Stopping a weekly compound does not mean it is gone in a week; it means roughly half of it is gone in a week. Four to five half-lives again to clear substantially. This is why "stopping" and "having stopped" are different states, and why a side effect can persist well past the last administration.
- Cmax
- The peak concentration reached after a dose. Often where acute side effects live.
- Tmax
- How long after administration that peak occurs.
- Bioavailability
- The fraction of an administered dose that reaches systemic circulation intact. Intravenous is 100% by definition; subcutaneous is typically high for peptides; oral is usually catastrophic.
- Downregulation
- Sustained stimulation causes cells to internalise receptors, reducing the number available. The same dose then produces less effect. Covered properly in PEP 401.
Route of administration
Where a compound is placed changes how fast it arrives and how much of it arrives.
- Subcutaneous. Into the fat layer beneath the skin. Slow, steady absorption from a poorly vascularised depot. The default route for peptides for exactly that reason.
- Intramuscular. Into muscle, which is better perfused. Faster absorption, higher peak, shorter duration.
- Intranasal. Used for a few small peptides that can cross the nasal mucosa. Bioavailability is low and variable.
- Oral. Generally non-viable without specialised formulation, per Module 01.
Note the trade-off embedded here: the route that produces the highest peak is not the route that produces the most total exposure. Different routes of the same compound are, pharmacologically, not interchangeable.
What you should be able to do now
- Describe, in five steps, how a peptide binding a surface receptor changes what a cell does.
- Distinguish affinity from efficacy and explain why an antagonist can bind more tightly than an agonist.
- Estimate time to steady state and time to washout from a half-life.
- Explain why judging a weekly compound after eight days is judging nothing.
Module 03 leaves the biology and deals with the legal category the compound occupies, which, unlike its pharmacology, changes depending on where you are standing.